Wuxi Vaccines Dengue Drug Substance Facility Wins Brazil ANVISA GMP...
Baca dalam 60 detik
- ANVISA's GMP certification validates Wuxi's manufacturing quality and compliance with Brazilian regulatory standards.
- This paves the way for large-scale production and distribution of dengue vaccines in Brazil, which reports over 1.
- 5 million cases annually.
ANVISA's GMP certification validates Wuxi's manufacturing quality and compliance with Brazilian regulatory standards. This paves the way for large-scale production and distribution of dengue vaccines in Brazil, which reports over 1. 5 million cases annually.
Wuxi Vaccines now positions as a key supplier in the global dengue vaccine race, competing with Takeda and Sanofi. Brazil's market alone represents a multi-billion-dollar opportunity as the government expands immunization programs. Certification also accelerates Wuxi's entry into other Latin American markets that recognize ANVISA standards.
The move aligns with Brazil's push for domestic vaccine production under its Health Economic-Industrial Complex strategy. By securing GMP certification early, Wuxi gains first-mover advantage in a region desperate for affordable dengue solutions. Production capacity expansion is likely next to meet anticipated surge in demand.
Power Move: ANVISA certification transforms Wuxi from a contract manufacturer into a strategic partner in Brazil's health sovereignty. Expect rapid scale-up and government contracts as dengue cases rise. Competitors must now match Wuxi's regulatory speed or lose Latin America.
This article was edited with AI assistance for readability. Read original here.
